Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Douglas LindManaging Director
Douglas Lind joined Burrill & Company as a Managing Director in the Venture Group in January 2012. Previously he served as Managing Director at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years experience in the life sciences industry, ranging from the practice of clinical medicine to work as a top tier Wall Street equity research analyst and venture capitalist. Throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs. He served as senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson & Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Myers Squibb), MedImmune (acquired by AstraZeneca), Agouron (acquired by Warner Lambert), Axys Pharmaceuticals (acquired by Celera) and Millenium Pharmaceuticals (acquired by Takeda Pharmaceuticals).
Dr. Lind is a graduate of the University of Iowa College of Medicine. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed residency training in internal medicine. He currently serves on the board of directors of Lentigen, MabVax, TMune, HyperMed Imaging, and Spectral Image.